Neoantigen-Targeted Dendritic Cell Vaccination in Lung Cancer Patients Induces Long-Lived T Cells Exhibiting the Full Differentiation Spectrum

Investigators presented the results of a Phase I clinical trial in which a dendritic cell vaccine targeting patient-individual neoantigens is evaluated in patients with resected non-small cell lung cancer.